Gland Pharma Limited (NSE: GLAND) shares were trading around ₹1,688, up about 0.8% in early Wednesday deals, after the Hyderabad-based injectables maker reported its third-quarter results. The stock trades well below its 52-week high of ₹2,131 and above its 52-week low near ₹1,278, reflecting a sideways to slightly softer trend over the past year.
Quarterly Results
Gland Pharma posted consolidated revenue of ₹16,954 million for the quarter ended Dec. 31, 2025 (Q3 FY26), a 22% year-on-year increase from ₹13,841 million in Q3 FY25. Gross profit rose 21% to ₹11,187 million, with gross margin at 66% versus 67% a year earlier. EBITDA increased 21% to ₹4,349 million, with margin steady at 26%. Adjusted EBITDA climbed 25% and maintained a 26% margin. Adjusted profit after tax grew 37% to ₹2,797 million, with an adj. PAT margin of 16% versus 15% in Q3 FY25. Nine-month revenue rose 12% to ₹46,879 million and adj. PAT was up 33% year-on-year.
Segment and Regional Performance
Revenue in the U.S. market increased 19% year-on-year, while Europe reported a 54% rise. India sales grew 32%, with modest gains in other regions. R&D expenses for the quarter were ₹650 million, reflecting increased product filings and development activity. The company launched nine molecules in the U.S. and filed multiple ANDAs during the quarter.
Growth Context
Gland Pharma delivered double-digit revenue growth both quarterly and for the nine-month period, with margins largely stable. The year-to-date figures indicate consistent expansion versus the prior fiscal period. Gross and adjusted profit metrics improved in absolute terms, while margin percentages remained largely similar to last year’s levels.
Market Reaction and Analyst Activity
There were no widely reported analyst upgrades, downgrades or price-target changes linked directly to today’s Q3 FY26 results. Previous analyst actions around the stock have occurred in prior quarters but none were disclosed in the latest session.
52-Week Share Performance
Over the past 12 months, Gland Pharma’s share price has fluctuated within a broad range of about ₹1,278 to ₹2,131, reflecting volatility around earnings and broader sector movements.